Rein Therapeutics announced that the U.S. Patent and Trademark Office (USPTO) granted two new patents related to Rein's lead product candidate, LTI-03, a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling, which is administered through dry powder inhalation.
U.S. Patent No. 12,280,088 and U.S. Patent No. 12,280,089, both titled, "Dry Powder Formulation of Caveolin-1 Peptides and Methods of Use Thereof", were issued on April 22, 2025. The patents cover LTI-03 dry powder inhalation formulation and its therapeutic use for treating various lung diseases including interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory or fibrotic lung conditions.
"These new patents strengthen the proprietary foundation of our inhaled peptide program and support the continued development of LTI-03 as a potential first-in-class therapeutic option for the treatment of IPF and other chronic and acute lung conditions," said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. "We believe that our dual-mechanism approach has the potential to address the significant unmet need in this patient population, and we look forward to initiating our Phase 2 clinical trial of LTI-03 in patients with IPF in the first half of this year."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!